Iron chelation therapy in myelodysplastic syndromes

Advances in Hematology

Volumn 2010, Issue , 2010, Pages

  Saglio, Giuseppe ^a   Messa, Emanuela ^a   Cilloni, Daniela ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT;

CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION RISK; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; NAUSEA; OUTCOME ASSESSMENT; PANCYTOPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL;

EID: 77954576886     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2010/756289     Document Type: Review

References (73)

1. Aul C., Bowen D. T., Yoshida Y., Pathogenesis, etiology and epidemiology of myelodysplastic syndromes Haematologica 1998 83 1 71 86
2. Greenberg P., Cox C., LeBeau M. M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J., International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 1997 89 6 2079 2088
3. List A. F., Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes Cancer Control 2008 15 4 29 39
4. Cazzola M., Malcovati L., Myelodysplastic syndromescoping with ineffective hematopoiesis The New England Journal of Medicine 2005 352 6 536 538
5. Malcovati L., Della Porta M. G., Cazzola M., Predicting survival and leukemic evolution in patients with myelodysplastic syndrome Haematologica 2006 91 12 1588 1590
6. Cabantchik Z. I., Breuer W., Zanninelli G., Cianciulli P., LPI-labile plasma iron in iron overload Best Practice and Research: Clinical Haematology 2005 18 2 277 287
7. Leitch H. A., Leger C. S., Goodman T. A., Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy Clinical Leukemia 2008 2 205 211
8. Rose C., Brechignac S., Vassilief D., Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM Blood 2007 110, article 249a
9. Sanz G., Nomdedeu B., Such E., Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome Blood 2008 112, article 640a
10. Armand P., Kim H. T., Cutler C. S., Ho V. T., Koreth J., Alyea E. P., Soiffer R. J., Antin J. H., Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation Blood 2007 109 10 4586 4588
11. Pullarkat V., Blanchard S., Tegtmeier B., Dagis A., Patane K., Ito J., Forman S. J., Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation Bone Marrow Transplantation 2008 42 12 799 805
12. Pullarkat V., Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009 114 26 5251 5255
13. Gattermann N., Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload Leukemia Research 2007 31 3 S10 S15
14. Alessandrino E. P., Amadori S., Barosi G., Cazzola M., Grossi A., Liberato L. N., Locatelli F., Marchetti M., Morra E., Rebulla P., Visani G., Tura S., Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the italian society of hematology Haematologica 2002 87 12 1286 1306
15. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., Parker J., Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes British Journal of Haematology 2003 120 2 187 200
16. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines. Myelodysplastic Syndromes. 2009, http://www.nccn.org/
17. Suzuki T., Tomonaga M., Miyazaki Y., Nakao S., Ohyashiki K., Matsumura I., Kohgo Y., Niitsu Y., Kojima S., Ozawa K., Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes International Journal of Hematology 2008 88 1 30 35
18. Bennett J. M., Consensus statement on iron overload in myelodysplastic syndromes American Journal of Hematology 2008 83 11 858 861
19. Wells R. A., Leber B., Buckstein R., Lipton J. H., Hasegawa W., Grewal K., Yee K., Olney H. J., Larratt L., Vickars L., Tinmouth A., Iron overload in myelodysplastic syndromes: a Canadian consensus guideline Leukemia Research 2008 32 9 1338 1353
20. Valent P., Krieger O., Stauder R., Wimazal F., Nsslinger T., Sperr W. R., Sill H., Bettelheim P., Pfeilstcker M., Iron overload in myelodysplastic syndromes (MDS)diagnosis, management, and response criteria: a proposal of the Austrian MDS platform European Journal of Clinical Investigation 2008 38 3 143 149
21. Mittelman M., Lugassy G., Merkel D., Tamary H., Sarid N., Rachmilewitz E., Hershko C., Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines Israel Medical Association Journal 2008 10 5 374 376
22. Kruszewski M., The role of labile iron pool in cardiovascular diseases Acta Biochimica Polonica 2004 51 2 471 480
23. Schafer A. I., Cheron R. G., Dluhy R., Clinical consequences of acquired transfusional iron overload in adults The New England Journal of Medicine 1981 304 6 319 324
24. Buja L. M., Roberts W. C., Iron in the heart. Etiology and clinical significance The American Journal of Medicine 1971 51 2 209 221
25. Mathew P., Tefferi A., Dewald G. W., Goldberg S. L., Su J., Hoagland H. C., Noel P., The 5q-syndrome: a single-institution study of 43 consecutive patients Blood 1993 81 4 1040 1045
26. Malcovati L., Della Porta M. G., Pascutto C., Invernizzi R., Boni M., Travaglino E., Passamonti F., Arcaini L., Maffioli M., Bernasconi P., Lazzarino M., Cazzola M., Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making Journal of Clinical Oncology 2005 23 30 7594 7603
27. Malcovati L., Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes Leukemia Research 2007 31 supplement 3 S2 S6
28. Malcovati L., Germing U., Kuendgen A., Della Porta M. G., Pascutto C., Invernizzi R., Giagounidis A., Hildebrandt B., Bernasconi P., Knipp S., Strupp C., Lazzarino M., Aul C., Cazzola M., Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes Journal of Clinical Oncology 2007 25 23 3503 3510
29. Cermak J., Kacirkova P., Mikulenkova D., Michalova K., Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts Leukemia Research 2009 33 11 1469 1474
30. Takatoku M., Uchiyama T., Okamoto S., Retrospective nationwide survey of Japanese patients with transfusiondependent MDS and aplastic anemia highlights the negative impact of iron overload onMorbiddity/mortality European Journal of Haematology 2007 78 487 494
31. Naka K., Muraguchi T., Hosh T. II, Hirao A., Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells Antioxidants and Redox Signaling 2008 10 11 1883 1894
32. Koptyra M., Falinski R., Nowicki M. O., Stoklosa T., Majsterek I., Nieborowska-Skorska M., Blasiak J., Skorski T., BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance Blood 2006 108 1 319 327
33. Rassool F. V., Gaymes T. J., Omidvar N., Brady N., Beurlet S., Pla M., Reboul M., Lea N., Chomienne C., Thomas N. S. B., Mufti G. J., Padua R. A., Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Research 2007 67 18 8762 8771
34. Chee C. E., Steensma D. P., Wu W., Hanson C. A., Tefferi A., Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts American Journal of Hematology 2008 83 8 611 613
35. Zurlo M. G., De Stefano P., Borgna-Pignatti C., Di Palma A., Piga A., Melevendi C., Di Gregorio F., Burattini M. G., Terzoli S., Survival and causes of death in thalassaemia major Lancet 1989 2 8653 27 30
36. Buja L. M., Roberts W. C., Iron in the heart. Etiology and clinical significance The American Journal of Medicine 1971 51 2 209 221
37. Konen E., Ghoti H., Goitein O., Winder A., Kushnir T., Eshet Y., Rachmilewitz E., No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique American Journal of Hematology 2007 82 11 1013 1016
38. Di Tucci A. A., Matta G., Deplano S., Gabbas A., Depau C., Derudas D., Caocci G., Agus A., Angelucci E., Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias Haematologica 2008 93 9 1385 1388
39. Chacko J., Pennell D. J., Tanner M. A., Hamblin T. J., Wonke B., Levy T., Thomas P. W., Killick S. B., Myocardial iron loading by magnetic resonance imaging T2 in good prognostic myelodysplastic syndrome patients on long-term blood transfusions British Journal of Haematology 2007 138 5 587 593
40. Jensen P. D., Jensen F. T., Christensen T., Eiskjaer H., Baandrup U., Nielsen J. L., Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferioxamine: indication of close relation between myocardial iron content and chelatable iron pool Blood 2003 101 4632 4639
41. Bullen J. J., Rogers H. J., Spalding P. B., Ward C. G., Natural resistance, iron and infection: a challenge for clinical medicine Journal of Medical Microbiology 2006 55 3 251 258
42. Kontoyiannis D. P., Chamilos G., Lewis R. E., Giralt S., Cortes J., Raad I. I., Manning J. T., Han X., Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation Cancer 2007 110 6 1303 1306
43. Altes A., Remacha A. F., Sarda P., Baiget M., Sureda A., Martino R., Briones J., Brunet S., Canals C., Sierra J., Early clinical impact of iron overload in stem cell transplantation. A prospective study Annals of Hematology 2007 86 6 443 447
44. Boelaert J. R., De Locht M., van Cutsem J., Kerrels V., Cantinieaux B., Verdonck A., Van Landuyt H. W., Schneider Y.-J., Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies Journal of Clinical Investigation 1993 91 5 1979 1986
45. Ibrahim A. S., Gebermariam T., Fu Y., Lin L., Husseiny M. I., French S. W., Schwartz J., Skory C. D., Edwards Jr. J. E., Spellberg B. J., The iron chelator deferasirox protects mice from mucormycosis through iron starvation Journal of Clinical Investigation 2007 117 9 2649 2657
46. Mahindra A., Sobecks R., Rybicki L., Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogenic hematopoietic stem cell transplantation British Journal of Haematology 2009 146 310 316
47. Au W. Y., Lam W. M., Chu W. C., Tam S., Wong W. K., Pennell D. J., Lie A. K., Liang R., A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels Transplantation Proceedings 2007 39 10 3369 3374
48. de Witte T., The role of iron in patients after bone marrow transplantation Blood Reviews 2008 22 2 S22 S28
49. von Bonsdorff L., Sahlstedt L., Ebeling F., Ruutu T., Parkkinen J., Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron FEMS Immunology and Medical Microbiology 2003 37 1 45 51
50. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M. D., Del Vecchio G. C., Romeo M. A., Forni G. L., Gamberini M. R., Ghilardi R., Piga A., Cnaan A., Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine Haematologica 2004 89 10 1187 1193
51. Gabutti V., Piga A., Results of long-term iron-chelating therapy Acta Haematologica 1996 95 1 26 36
52. Neufeld E. J., Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions Blood 2006 107 9 3436 3441
53. Cappellini M. D., Pattoneri P., Oral iron chelators Annual Review of Medicine 2009 60 25 38
54. Kontoghiorghes G. J., Pattichi K., Hadjigavriel M., Kolnagou A., Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1) Transfusion Science 2000 23 3 211 223
55. Cappellini M. D., Long-term efficacy and safety of deferasirox Blood Reviews 2008 22 2 S35 S41
56. Cappelini M. D., Choen A., Piga A., A phase 3 study of deferasirox (ICL670), a once-daily oral chelator, in patients with-thalassemia Blood 2006 107 3455 3462
57. Piga A., Galanello R., Forni G. L., Cappellini M. D., Origa R., Zappu A., Donato G., Bordone E., Lavagetto A., Zanaboni L., Sechaud R., Hewson N., Ford J. M., Opitz H., Albert D., Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload Haematologica 2006 91 7 873 880
58. Vichinsky E., Onyekwere O., Porter J., Swerdlow P., Eckman J., Lane P., Files B., Hassell K., Kelly P., Wilson F., Bernaudin F., Forni G. L., Okpala I., Ressayre-Djaffer C., Alberti D., Holland J., Marks P., Fung E., Fischer R., Mueller B. U., Coates T., A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease British Journal of Haematology 2007 136 3 501 508
59. Porter J., Galanello R., Saglio G., Neufeld E. J., Vichinsky E., Cappellini M. D., Olivieri N., Piga A., Cunningham M. J., Soulires D., Gattermann N., Tchernia G., Maertens J., Giardina P., Kwiatkowski J., Quarta G., Jeng M., Forni G. L., Stadler M., Cario H., Debusscher L., Porta M. D., Cazzola M., Greenberg P., Alimena G., Rabault B., Gathmann I., Ford J. M., Alberti D., Rose C., Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study European Journal of Haematology 2008 80 2 168 176
60. Gattermann N., Schmid M., Della Porta M., Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial Blood 2008 112, article 633a
61. Leitch H. A., Vickars L. M., Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? Hematology 2009 664 672
62. Jensen P. D., Jensen I. M., Ellegaard J., Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome British Journal of Haematology 1992 80 1 121 124
63. Jensen P. D., Heickendorff L., Pedersen B., Bendix-Hansen K., Jensen F. T., Christensen T., Boesen A. M., Ellegaard J., The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload British Journal of Haematology 1996 94 2 288 299
64. Smeets M. E. P., Vreugdenhil S., Holdrinet R. S. G., Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis American Journal of Hematology 1996 51 3 243 244
65. Di Tucci A. A., Murru R., Alberti D., Rabault B., Deplano S., Angelucci E., Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670) European Journal of Haematology 2007 78 6 540 542
66. Messa E., Cilloni D., Messa F., Arruga F., Roetto A., Saglio G., Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis Acta Haematologica 2008 120 2 70 74
67. Capalbo S., Spinosa G., Franzese M. G., Palumbo G., Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements Acta Haematologica 2009 121 1 19 20
68. List A. F., Baer M. R., Steensma D., Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes (MDS) Blood 2008 112, article 634a
69. Camaschella C., Campanella A., De Falco L., Boschetto L., Merlini R., Silvestri L., Levi S., Iolascon A., The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload Blood 2007 110 4 1353 1358
70. Hartmann J., Sinzig U., Wulf G., Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS Blood 2008 112, article 2694a
71. Messa E., Carturan S., Maff C., Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. In press
72. Steensma D. P., Myelodysplasia paranoia: iron as the new radon Leukemia Research 2009 33 9 1158 1163
73. Tefferi A., Stone R. M., Iron chelation therapy in myelodysplastic syndromeCui bono? Leukemia 2009 23 8 1373